The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma

被引:47
|
作者
D'Amico, Randy S. [1 ,2 ]
Cloney, Michael B. [1 ]
Sonabend, Adam M. [2 ]
Zacharia, Brad [2 ]
Nazarian, Matthew N. [1 ]
Iwamoto, Fabio M. [3 ]
Sisti, Michael B. [2 ]
Bruce, Jeffrey N. [1 ,2 ]
McKhann, Guy M., II [2 ]
机构
[1] Columbia Univ, Coll Phys & Surg, Gabriele Bartoli Brain Tumor Res Lab, New York, NY 10027 USA
[2] Columbia Univ, Med Ctr, Dept Neurol Surg, New York, NY USA
[3] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA
关键词
Complications; Craniotomy; Elderly; Glioblastoma; Recurrent glioblastoma; RADIOTHERAPY PLUS CONCOMITANT; NEWLY-DIAGNOSED GLIOBLASTOMA; SOFT-TISSUE INFECTIONS; PERIOPERATIVE COMPLICATIONS; ADJUVANT TEMOZOLOMIDE; SURGICAL OUTCOMES; RESECTION; MULTIFORME; GLIOMA; CARE;
D O I
10.1016/j.wneu.2015.05.072
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Glioblastoma (GBM) occurs more commonly in elderly patients. However, these patients are often excluded from clinical trials. The absence of solid evidence has resulted in a nihilistic view of GBM in the elderly and a traditionally conservative treatment approach. In particular, the safety of surgical resection for both primary and recurrent GBM is poorly understood in elderly patients. METHODS: In a retrospective cohort of patients aged >= 65 years, we examined selection for biopsy, surgical resection, and reoperation for recurrent disease. We also analyzed complication rates after initial resection and reoperation for recurrent disease. We identified 319 elderly patients with pathologically proven GBM who underwent a total of 274 craniotomies at our institution between 2000 and 2012. Events were reported according to the methods used in the Glioma Outcomes Project. RESULTS: The overall rate of complications after resection was 21.9%, with a rate of neurological complications of 7.7%. The rates of neurological, regional, and systemic complications were not significantly different after initial craniotomy and reoperation for GBM in elderly patients. Reoperations were not associated with an increased risk of complications. Low cardiovascular risk, improved functional status, and hemispheric GBM were associated with selection for more aggressive surgical treatment. Younger age and improved functional status were associated with a reduced likelihood of complications. CONCLUSIONS: We conclude that in select patients, age alone should not preclude the decision to pursue aggressive surgical management.
引用
收藏
页码:913 / 919
页数:7
相关论文
共 50 条
  • [1] Surgery for Glioblastoma in Elderly Patients
    Nibali, Marco Conti
    Gay, Lorenzo G.
    Sciortino, Tommaso
    Rossi, Marco
    Caroli, Manuela
    Bello, Lorenzo
    Riva, Marco
    [J]. NEUROSURGERY CLINICS OF NORTH AMERICA, 2021, 32 (01) : 137 - 148
  • [2] Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
    Matteo Santoni
    Silvia Scoccianti
    Ivan Lolli
    Maria Grazia Fabrini
    Giovanni Silvano
    Beatrice Detti
    Franco Perrone
    Giuseppina Savio
    Roberto Iacovelli
    Luciano Burattini
    Rossana Berardi
    Stefano Cascinu
    [J]. Journal of Neuro-Oncology, 2013, 113 : 397 - 401
  • [3] Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
    Santoni, Matteo
    Scoccianti, Silvia
    Lolli, Ivan
    Fabrini, Maria Grazia
    Silvano, Giovanni
    Detti, Beatrice
    Perrone, Franco
    Savio, Giuseppina
    Iacovelli, Roberto
    Burattini, Luciano
    Berardi, Rossana
    Cascinu, Stefano
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2013, 113 (03) : 397 - 401
  • [4] Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma
    Klein, Johann
    Juratli, Tareq A.
    Radev, Yordan
    Daubner, Dirk
    Soucek, Silke
    Schackert, Gabriele
    Krex, Dietmar
    [J]. ONCOLOGY, 2017, 93 (01) : 43 - 50
  • [5] Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
    Hao Lin
    Xinli Zhou
    Xiaofang Sheng
    Xiaohua Liang
    [J]. Drugs in R&D, 2023, 23 : 239 - 244
  • [6] Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
    Lin, Hao
    Zhou, Xinli
    Sheng, Xiaofang
    Liang, Xiaohua
    [J]. DRUGS IN R&D, 2023, 23 (03) : 239 - 244
  • [7] Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
    Fasano, Morena
    Pirozzi, Mario
    Famiglietti, Vincenzo
    Facchini, Sergio
    Caterino, Marianna
    Caroprese, Mara
    Barillaro, Angela
    Di Giovanni, Ilaria
    Auriemma, Annunziata
    Fattoruso, Silvia Ileana Sara
    Somma, Teresa
    Solari, Domenico
    Bocchetti, Marco
    Conson, Manuel
    Pacelli, Roberto
    Ciardiello, Fortunato
    Addeo, Raffaele
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2023, 18 (02)
  • [8] Primary versus recurrent surgery for glioblastoma—a prospective cohort study
    Maja Chava Rubin
    Lisa Millgård Sagberg
    Asgeir Store Jakola
    Ole Solheim
    [J]. Acta Neurochirurgica, 2022, 164 : 429 - 438
  • [9] Safety of axitinib plus avelumab in patients with recurrent glioblastoma
    Ben Salama, Laila
    Duerinck, Johnny
    Du Four, Stephanie
    Awada, Gil
    Fischbuch, Lydia
    De Cremer, Jennifer
    Rogiers, Anne
    Neyns, Bart
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
    Rimas V. Lukas
    Jordi Rodon
    Kevin Becker
    Eric T. Wong
    Kent Shih
    Mehdi Touat
    Marcella Fassò
    Stuart Osborne
    Luciana Molinero
    Carol O’Hear
    William Grossman
    Joachim Baehring
    [J]. Journal of Neuro-Oncology, 2018, 140 : 317 - 328